Product Description
The research-grade biosimilar is a humanized IgG4 kappa monoclonal antibody that targets IL-5. IL-5 is a proinflammatory cytokine that mediates recruitment, activation, growth, differentiation, and survival of eosinophils. Increased production of eosinophils is associated with allergic and non-allergic forms of asthma. The antibody specifically binds to the ERRR region (between amino acids 89-92) of the IL-5, which is necessary for the interaction with the IL-5 receptor located on the eosinophil cell surface. This results in inhibition of IL-5 mediated signaling, prevents maturation of the eosinophils, and eosinophil-mediated inflammation. The original drug received approval from the FDA as an add-on treatment for patients suffering from severe asthma with an eosinophilic phenotype.
Biovision | A2167 | Anti-IL-5 (Reslizumab), Humanized Antibody DataSheet
Antibody Target: IL-5
Target Alternative Name: CEP-38072, DCP 835, DCP-835, SCH-55700, SCH55700, EDF, TRF, IL5
Tag Line: The biosimilar antibody is a humanized monoclonal antibody that targets IL-5, disrupts IL-5 mediated signaling, and thus reduces the production and survival of eosinophils, and eosinophil-mediated inflammation.
Category: Biosimilars
Host: Recombinant
Isotype: IgG4
Species Reactivities: Human
Immunogen Sequence: Human IL-5
Accession #: DB06602
Gene ID:
Appearance: Colorless liquid
Form: Liquid
Concentration: 1 mg/ml
Formulation: In PBS, pH 7.5
Purification: Protein A purified
Application:
Positive Control:
Application And Usages:
Country of Animal Origin: USA
Country of Manufacture: USA
Usage: For Research Use Only! Not to be used in humans.
Handling: The antibody solution should be gently mixed before use.
Western Blot Verified: FALSE
Immunocytochemistry Verified: FALSE
Immunofluorescence Verified: FALSE
Immunoprecipitation Verified: FALSE
FACS Verified: FALSE
ELISA Verified: FALSE
ChIP Verified: FALSE
Dot Blot Verified: FALSE
Flow Cytometry Verified: FALSE